Versartis Inc (NASDAQ:VSAR) shares dropped 8.4% on Thursday . The company traded as low as $1.40 and last traded at $1.42. Approximately 504,046 shares traded hands during mid-day trading, a decline of 0% from the average daily volume of 506,441 shares. The stock had previously closed at $1.55.

Separately, ValuEngine upgraded Versartis from a “hold” rating to a “buy” rating in a report on Monday, August 13th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and two have issued a buy rating to the stock. Versartis currently has a consensus rating of “Hold” and a consensus target price of $5.13.

The company has a debt-to-equity ratio of 0.11, a quick ratio of 16.99 and a current ratio of 16.99.

Versartis (NASDAQ:VSAR) last issued its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.96) by $0.69. equities analysts anticipate that Versartis Inc will post -3.15 EPS for the current fiscal year.

Several large investors have recently modified their holdings of VSAR. Deutsche Bank AG increased its position in shares of Versartis by 90.0% during the 4th quarter. Deutsche Bank AG now owns 82,299 shares of the biopharmaceutical company’s stock worth $180,000 after purchasing an additional 38,975 shares during the last quarter. Schwab Charles Investment Management Inc. grew its position in Versartis by 156.0% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 129,381 shares of the biopharmaceutical company’s stock valued at $214,000 after acquiring an additional 78,842 shares in the last quarter. California Public Employees Retirement System acquired a new position in Versartis in the 1st quarter valued at about $124,000. Dimensional Fund Advisors LP grew its position in Versartis by 13.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 617,702 shares of the biopharmaceutical company’s stock valued at $1,019,000 after acquiring an additional 73,754 shares in the last quarter. Finally, GSA Capital Partners LLP grew its position in Versartis by 82.1% in the 1st quarter. GSA Capital Partners LLP now owns 159,500 shares of the biopharmaceutical company’s stock valued at $263,000 after acquiring an additional 71,900 shares in the last quarter. 38.64% of the stock is owned by hedge funds and other institutional investors.

About Versartis (NASDAQ:VSAR)

Recommended Story: Book Value Per Share – BVPS

Receive News & Ratings for Versartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis and related companies with MarketBeat.com's FREE daily email newsletter.